US FDA approves Liquidia’s Yutrepia (treprostinil) inhalation powder for patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease

23 May 2025 - Yutrepia is designed to enhance deep-lung delivery with an easy-to-use device requiring low inspiratory effort. ...

Read more →

Relief Therapeutics receives FDA rare paediatric disease designation for RLF-TD011

22 May 2025 - Relief Therapeutics today announced that the US FDA has granted rare paediatric disease designation to RLF-TD011 ...

Read more →

FDA approves Genentech’s Susvimo for diabetic retinopathy

22 May 2025 - Genentech announced today that the US FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment ...

Read more →

Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease

22 May 2025 - Approval based on the positive MATINEE and METREX Phase 3 trials. ...

Read more →

Belite Bio announces FDA granting of breakthrough therapy designation for tinlarebant for the treatment of Stargardt disease

21 May 2025 - Belite Bio today announced that the US FDA has granted breakthrough therapy designation for tinlarebant for ...

Read more →

FDA takes steps to enhance state importation programs to help lower prescription drug prices

21 May 2025 - The US FDA is continuing to take steps to help state importation programs provide safe, effective and ...

Read more →

Moderna provides update on BLA submission for combination vaccine against influenza and COVID-19

21 May 2025 -  Moderna today announced that in consultation with the US FDA, the Company has voluntarily withdrawn the ...

Read more →

US FDA grants approval for Jivi anti-hemophilic factor (recombinant), PEGylated-aucl in paediatric patients 7 to under 12 years of age with haemophilia A

19 May 2025 - Bayer announced that the US FDA has approved Jivi, a recombinant DNA-derived, extended half-life factor VIII ...

Read more →

US FDA approves BLA for Novavax's COVID-19 vaccine

19 May 2025 - Nuvaxovid is the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the US. ...

Read more →

Zai Lab receives US FDA fast track designation for ZL-1310, a DLL3 targeted antibody drug conjugate, for treatment of extensive stage small cell lung cancer

19 May 2025 - The Company is on track to initiate a pivotal study for ZL-1310 in small cell lung ...

Read more →

FDA clears first blood test used in diagnosing Alzheimer’s disease

16 May 2025 - New test provides less invasive option, reduces reliance on PET scans and increases diagnosis accessibility. ...

Read more →

PharmaTher announces FDA extends review period for ketamine; new approval goal date 9 August 2025

16 May 2025 -  PharmaTher today announced the US FDA has extended the approval goal date for the review of ...

Read more →

Amneal receives US FDA approval for Brekiya (dihydroergotamine mesylate) injection for the acute treatment of migraine and cluster headaches in adults

15 May 2025 - Product will be available for appropriate patients in the second half of 2025 ...

Read more →

Kaerus Bioscience's lead candidate KER-0193 granted orphan drug designation and rare paediatric drug designation by US FDA for treatment of Fragile X syndrome

14 May 2025 - Kaerus Bioscience today announces that its lead candidate KER-0193 has been granted both orphan drug designation and ...

Read more →

FDA grants regenerative medicine advanced therapy designation for BrainChild Bio’s B7-H3 CAR T-cell therapy for incurable paediatric brain tumours

15 May 2025 - BrainChild Bio advancing BCB-276 towards BLA submission with a single pivotal Phase 2 trial planned to ...

Read more →